Leading player in the women's health market
) continues to leap forward with positive data supporting the
adoption of its tomosynthesis technology. The company stated that
the latest online publication of a new study by
supports the efficacy of the company's tomosynthesis technology
over the 2-dimensional (2D) imaging in breast cancer screening
CEPHEID INC (CPHD): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
HOLOGIC INC (HOLX): Free Stock Analysis
MINDRAY MEDICAL (MR): Free Stock Analysis
To read this article on Zacks.com click here.
paper is the first peer-reviewed publication to examine the
performance of double reading of 2D mammography in contrast to
double reading of 2D mammography plus tomosynthesis imaging in a
large prospective clinical study. The study - 'Prospective Trial
Comparing Full-field Digital Mammography (FFDM) versus Combined
FFDM and Tomosynthesis in a Population-based Screening Programme
Using Independent Double Reading with Arbitration' shows the
technical advancement of Hologic's breast tomosynthesis
The study encompassed 12,621 screening examinations of women
participating in the Oslo Tomosynthesis Screening Trial. The
researchers concluded that double-reading of tomosynthesis based
examinations decreased false-positive interpretations by 18%.
Also, double-reading of tomosynthesis based examinations improved
breast cancer detection by 30%.
The Oslo data further supports the use of Hologic's tomosynthesis
technology to improve detection rate. Management is optimistic
that the proven strong clinical benefits of its tomosynthesis
technology should improve adoption rates.
Earlier, in Jan 2013, the company disclosed results from the
crucial Oslo clinical study which advocates the use of Hologic's
3D breast tomosynthesis screening technology in addition to the
2D breast screening exam. Management states this to be a landmark
revelation as the Oslo trial is the first large-scale prospective
study to support its 3D tomosynthesis technology platform.
We believe that publication of peer-reviewed study should ramp up
adoption rates and support Hologic's efforts to gain
reimbursement for its tomosynthesis technology. Notably, company
expectations from the tomosynthesis technology are very high.
Hologic's consistent efforts to promote the technology are likely
to yield positive results.
Currently, the stock carries a Zacks Rank #3 (Hold). While we
remain on the sidelines for Hologic, other healthcare stocks such
), carrying a Zacks Rank #1 (Strong Buy) warrant a look.
Mindray Medical International Limited
), carrying a Zacks Rank #2 (Buy) is also worth considering.